Holen Sie sich die Stockscreener-App
4.41
1.85%
0.08
Schlusskurs vom Vortag:
$4.33
Offen:
$4.32
24-Stunden-Volumen:
124.30K
Relative Volume:
0.63
Marktkapitalisierung:
$199.75M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
-9.00
EPS:
-0.49
Netto-Cashflow:
$-27.23M
1W Leistung:
+4.50%
1M Leistung:
+0.00%
6M Leistung:
-28.76%
1J Leistung:
-63.73%
1-Tages-Spanne:
$4.29
$4.45
1-Wochen-Bereich:
$4.20
$4.50
52-Wochen-Spanne:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Firmenname
Y Mabs Therapeutics Inc
Sektor
Branche
Telefon
646-885-8505
Adresse
202 CARNEGIE CENTER, PRINCETON, NY
Vergleichen Sie YMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.41 | 191.15M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Eingeleitet | Truist | Buy |
| 2023-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-04-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-27 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-10-31 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-03 | Fortgesetzt | Guggenheim | Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-05-01 | Eingeleitet | Janney | Buy |
| 2020-04-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Eingeleitet | Wedbush | Outperform |
| 2019-04-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-10-16 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
What drives Y mAbs Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
What analysts say about Y mAbs Therapeutics Inc. stockConsistently high returns - Autocar Professional
Y mAbs Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional
Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks
Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com
What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser
Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser
2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360
Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India
Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa
Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World
Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail
Oppenheimer Adjusts Target Price for Y-mAbs Therapeutics (YMAB) - GuruFocus
Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):